Changes to the Code
S. 832 · Ensuring Pathways to Innovative Cures Act of 2025 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
EPIC Act of 2025
In committee · step 2 of 5
42 U.S.C. § 1320f–1 Selection of negotiation-eligible drugs as selected drugs
+2 −01 of 2 shown
2 changes the bill asks for here, 1 carried out
- Not carried out:
by striking year, at least 7 and inserting “year—(I) for initial price applicability years 2026 and 2027, at least 7; and
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: striking QTEXT and inserting “ year — QCONTENT; and - Carried out:
by adding at the end the following:
(II) for initial price applicability year 2028 and each subsequent initial price applicability year, at least 11 years will have elapsed since the date of such approval; and.
§ 1320f–1(e)(1)In general(A)–(B)
Start of § 1320f–1 to (e)(1)(A) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (A)(i) | (i) | (i) | ||
| that is approved under section 355(c) of title 21 and is marketed pursuant to such approval; | that is approved under section 355(c) of title 21 and is marketed pursuant to such approval; | |||
| (A)(ii) | (ii) | (ii) | ||
| for which, as of the selected drug publication date with respect to such initial price applicability year, at least 7 years will have elapsed since the date of such approval; and | for which, as of the selected drug publication date with respect to such initial price applicability year, at least 7 years will have elapsed since the date of such approval; and | |||
| (A)(ii)(II) | (II) [inserted: ] | |||
| [inserted: for initial price applicability year 2028 and each subsequent initial price applicability year, at least 11 years will have elapsed since the date of such approval; and] | ||||
| (A)(iii) | (iii) | (iii) | ||
| that is not the listed drug for any drug that is approved and marketed under section 355(j) of such title. | that is not the listed drug for any drug that is approved and marketed under section 355(j) of such title. | |||
| (B) | (B) Biological products | (B) Biological products | ||
| A biological product— | A biological product— | |||
Rest of § 1320f–1 unchanged